Forest lines up products to fill Lexapro gap as Linzess and Tudorza launched in US
This article was originally published in Scrip
Executive Summary
Loss of patent protection for the depression and anxiety drug Lexapro (escitalopram oxalate) continues to eat away Forest Laboratories' earnings, but the New York-based company is working to replace revenue from the selective serotonin reuptake inhibitor (SSRI) with sales from new products, including the irritable bowel syndrome (IBS) therapy Linzess (linaclotide) that launched in partnership with Ironwood Pharmaceuticals in December.